Reported 1 day ago
Soleno Therapeutics Inc. has reported that its new drug Vykat XR, approved for treating insatiable hunger in Prader-Willi syndrome, is exceeding sales expectations. Anticipating revenues of $31 to $33 million for the quarter ending June 30, initial demand appears strong, with around 646 start forms received from 295 physicians since its approval on March 26. This reflects a promising start for the biopharmaceutical company in 2025.
Source: YAHOO